Domain: Web Application
Client Profile: www.coreaccessgroup.com
Technology: ASP.Net, AJAX, MS SQL Server, JQuery, Javascript, Third Part Tools
Execution & Delivery: Agile; Offshore Model
The Hemophilia market is expected to grow at an average rate of 5.9% through 2017, expanding to $11.4 billion in value by 2016 (Morningstar Healthcare Observer, Jan 2013 report). New entrants continue to seep into this Baxter™, Bayer™ and Pfizer™ dominated recombinant protein market.
In a competitive scenario, Baxter™ turned to Core Access™ to help sketch a strategy that would supposedly help them retain market share and penetrate further into the biggest Hemophilia market – Hemophilia A.
In order to address this challenge, our team at Sagarsoft™, in consultation with Core Access™ created a robust, rapid computing graphical statistical application to help unravel the changing face of Hemophilia pharmaceutical market data.
The Hemophilia market for recombinant factor proteins is growing at a rapid pace. Presently, new mature forms of Factor VIII and IX for Hemophilia are gaining market position. In this competitive scenario, Baxter™ can afford to dominate the segment strictly through a scientifically planned market access strategy – an intuitive market data scan that was planned by Core Access™ and executed computationally by Sagarsoft™.
.
Our mature team and processes drastically cut down on development time (50-70%) even during first encounter with new technologies.
Transparent decision making with agreed upon milestones guarantee an accurate, high performance, intuitive application portfolio